Tanya G. Weinstock

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> Allele

Edith T. Zemanick, Jennifer L. Taylor‐Cousar, Jane C. Davies et al. · American Journal of Respiratory and Critical Care Medicine · 2021 · 261 citations · Full text

A Controlled Trial of CPAP Therapy on Metabolic Control in Individuals with Impaired Glucose Tolerance and Sleep Apnea

Tanya G. Weinstock, Xuelei Wang, Michael Rueschman et al. · SLEEP · 2012 · 182 citations · Full text

Predictors of Obstructive Sleep Apnea Severity in Adenotonsillectomy Candidates

Tanya G. Weinstock, Carol L. Rosen, Carole L. Marcus et al. · SLEEP · 2014 · 160 citations · Full text

Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for <i>F508del</i> and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study

Marcus Mall, Rossa Brugha, Silvia Gärtner et al. · American Journal of Respiratory and Critical Care Medicine · 2022 · 126 citations · Full text

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele

Jennifer L. Goralski, Jordana E. Hoppe, Marcus Mall et al. · American Journal of Respiratory and Critical Care Medicine · 2023 · 113 citations · Full text